Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2002

01-06-2002 | Original Article

Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients

Authors: Raul C. Maranhão, Silvia R. Graziani, Nise Yamaguchi, Roberto F. Melo, Maria C. Latrilha, Debora G. Rodrigues, Ricardo D. Couto, Shirley Schreier, Antonio C. Buzaid

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2002

Login to get access
Metadata
Title
Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients
Authors
Raul C. Maranhão
Silvia R. Graziani
Nise Yamaguchi
Roberto F. Melo
Maria C. Latrilha
Debora G. Rodrigues
Ricardo D. Couto
Shirley Schreier
Antonio C. Buzaid
Publication date
01-06-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0437-3

Other articles of this Issue 6/2002

Cancer Chemotherapy and Pharmacology 6/2002 Go to the issue

Original Article

A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti-ras peptide

Original Article

Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model

Original Article

Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles

Original Article

Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins

Original Article

Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer

Original Article

Differential cytostatic effect of sodium salicylate in human colorectal cancers using an individualized histoculture system
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits